260 results on '"Salud, Antonieta"'
Search Results
2. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
3. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis
4. Secreted Phospholipases A2: Drivers of Inflammation and Cancer.
5. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
6. Corrigendum to “Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 201 (2024) 104416]
7. MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions
8. Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research
9. Utility of CEA and CA 15-3 Measurements in Non-Purulent Pleural Exudates in the Diagnosis of Malignancy: A Single-Center Experience
10. Utilidad de la medición de CEA y CA 15-3 en los exudados pleurales no purulentos para diagnosticar malignidad: experiencia de un único centro
11. Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
12. Predictors of Indwelling Pleural Catheter Removal and Infection: A Single-center Experience With 336 Procedures
13. Predictors of Indwelling Pleural Catheter Removal and Infection: A Single-center Experience With 336 Procedures
14. Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402
15. PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance
16. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
17. Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion
18. Accuracy of Fluorodeoxyglucose-PET Imaging for Differentiating Benign From Malignant Pleural Effusions: A Meta-analysis
19. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
20. A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
21. Sedación paliativa: situación actual y áreas de mejora
22. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
23. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
24. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
25. Cell-Free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions
26. Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer
27. Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
28. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
29. TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions
30. Clinical features and survival of lung cancer patients with pleural effusions
31. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions
32. Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities
33. El Registre poblacional de càncer a Lleida en zones urbanes i rurals. Resultats de l’any 2014
34. Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain
35. Tumor Type Influences the Effectiveness of Pleurodesis in Malignant Effusions
36. Prognostic significance of pleural fluid data in patients with malignant effusion
37. Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
38. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions
39. Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer
40. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
41. Prognostic Factors Involved in the Epithelial–Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis
42. Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.
43. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
44. Use of a Panel of Tumor Markers (Carcinoembryonic Antigen, Cancer Antigen 125, Carbohydrate Antigen 15–3, and Cytokeratin 19 Fragments) in Pleural Fluid for the Differential Diagnosis of Benign and Malignant Effusions
45. Activity and Safety of Oxaliplatin with Weekly 5-Fluorouracil Bolus and Low-Dose Leucovorin as First-Line Treatment for Advanced Colorectal Cancer
46. Activity of oxaliplatin (OXA) with weekly 5-fluorouracil (5-FU) bolus and low-dose folinic acid (FA) as first line treatment for advanced colorectal cancer (ACC)
47. MULTICENTER PHASE II STUDY OF OXALIPLATIN (OXA) EVERY TWO WEEKS IN COMBINATION WITH WEEKLY 5-FU BOLUS AND FOLINIC ACID (FA) AS FIRST LINE TREATMENT FOR ADVANCED COLORECTAL CANCER (ACC): 2244
48. Paclitaxel (P), gemcitabine (G) and cisplatin (c) in non-resectable non-small cell lung cancer (NSCLC).
49. Should a Cytologic Study Be Ordered in Transudative Pleural Effusions?
50. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.